Related Experiment Video

Updated: Sep 18, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

The role of Stat5 in estrogen receptor-positive breast cancer

Hiroko Yamashita1, Hirotaka Iwase

  • 1Department of Surgery II, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-ku, Nagoya 467-8601, Japan. hirokoy@med.nagoya-cu.ac.jp

Breast Cancer (Tokyo, Japan)
|December 3, 2002
PubMed

Insights

Targeting signal transducer and activator of transcription 5 (Stat5) may offer a new strategy for treating estrogen receptor (ER)-positive breast cancer by suppressing ER activity and inducing cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Estrogen receptor (ER) targeted therapies are crucial for breast cancer treatment.
  • Growth factor signaling pathways are emerging as effective therapeutic targets.
  • Understanding ER and growth factor pathway interactions is key to overcoming endocrine resistance.

Purpose of the Study:

  • To investigate the role of signal transducer and activator of transcription 5 (Stat5) in ER-positive breast cancer progression.
  • To explore the potential of targeting Stat5 as a novel therapeutic strategy.

Main Methods:

  • Analysis of Stat5 role in ER-positive breast cancer cell lines (T47D and MCF7).
  • Utilizing adenoviral-mediated dominant-negative Stat5 to induce apoptosis.
  • Assessing Stat5b constitutive activation in these cell lines.

Main Results:

  • Stat5b was constitutively activated in ER-positive breast cancer cells (T47D and MCF7).
  • Adenoviral-mediated dominant-negative Stat5 induced apoptosis in T47D cells.
  • No apoptosis was observed in caspase-3 negative MCF7 cells, indicating a caspase-dependent mechanism.

Conclusions:

  • Stat5 activation plays a significant role in the progression of ER-positive breast cancer.
  • Targeting Stat5 may represent a novel therapeutic approach to inhibit ER activity.
  • Inducing apoptosis via Stat5 inhibition could be a viable strategy for Stat5-activated, ER-positive breast cancer.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines08:05

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines

Published on: February 24, 2026

Related Concept Videos

Role of ER in the Secretory Pathway01:17

Role of ER in the Secretory Pathway

Eukaryotic cells have a special pathway that enables communication between various intracellular membrane-bound compartments and also with the extracellular environment. This pathway is termed as the secretory pathway.
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...